Medical Device News Magazine

Dr Paloma H Giangrande Appointed CTO At Eleven Therapeutics | A Prominent Figure In Nucleic Acid Therapeutics for Over a Decade

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...


  • Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr Paloma H Giangrande as the company’s Chief Technology Officer (CTO).

Dr Paloma H Giangrande

Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr Paloma H Giangrande as the company’s Chief Technology Officer (CTO). Dr. Giangrande, an esteemed leader in the field of nucleic acid therapeutics, will play a pivotal role in advancing the company’s core xRNA technologies and platforms.

Bringing a wealth of experience, Dr. Giangrande has been a prominent figure in nucleic acid therapeutics for over a decade. Her groundbreaking work at the University of Iowa involved pioneering multiple nucleic acid technologies. Subsequently, she held key leadership roles at renowned biotechnology companies, including as Director of Rare Diseases at Moderna, where she spearheaded mRNA therapeutic programs for rare genetic diseases. Her most recent position was as VP of Platform and Discovery at Wave Life Sciences, leading the groundbreaking RNA Editing program to a first-in-human stage. Dr. Giangrande currently holds the prestigious role of Editor-in-Chief at Molecular Therapy Nucleic Acids, the field’s foremost scientific journal.

In her new capacity as CTO at Eleven Therapeutics, Dr. Giangrande will drive the strategic direction for the company’s core xRNA technologies and platforms. Her expertise will be instrumental in integrating these cutting-edge technologies into therapeutic applications, solidifying Eleven Therapeutics’ position as a leader in nucleic acid therapeutics.

Prof. Yaniv Erlich, CEO and Co-Founder of Eleven Therapeutics Comments

“We are thrilled to welcome Dr. Paloma Giangrande to Eleven Therapeutics. Her expertise specifically in our company’s field of specialization and her remarkable leadership track record will significantly bolster our capabilities in advancing innovation. Dr. Giangrande’s appointment represents a strategic milestone as we continue to revolutionize mRNA therapeutics and pave the way for transformative new horizons in the treatment of diseases with unmet needs.”

Dr Paloma H Giangrande Replied

“Joining Eleven Therapeutics is an exciting opportunity for me to apply my expertise to crucial biotechnological challenges,” said Dr. Giangrande. “I’m enthusiastic about contributing to the groundbreaking research conducted here. Along Eleven’s strong team and innovative approach, I look forward to leveraging my strategic insights and experience to accelerate the development of cutting-edge nucleic acid therapeutics, and beyond.”


Dr Paloma H Giangrande officially assumed her role as Chief Technology Officer at Eleven Therapeutics on January 2nd, 2024.

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.